Cardiovascular Health

The Pharmacy Times® Cardiovascular Health resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?
[[thumbnail_alt_text]]
According to a recent study in the Heart journal, regular tub bathing is linked to a lower risk of death from heart disease and stroke.
[[thumbnail_alt_text]]
Study shows rivaroxaban (Xarelto, Bayer) following nonmajor orthopedic surgery reduced the risk of major venous thromboembolism by approximately 75% compared with enoxaparin.
[[thumbnail_alt_text]]
Patients with symptomatic peripheral artery disease who took rivaroxaban (Xarelto, Bayer) saw a 15% reduction in the risk of major adverse limb and cardiovascular events.
[[thumbnail_alt_text]]
A recent study has detailed information on the potential dangers and the application of QTc monitoring to guide treatment when using drugs that can cause heart rhythm changes.
[[thumbnail_alt_text]]
A prespecified exploratory analysis using the safety data from the 3 trials indicated fewer major adverse cardiovascular events (MACE) with inclisiran compared with placebo.
[[thumbnail_alt_text]]
All 3 trials reached their primary endpoints, specifically percentage change in low-density lipoprotein cholesterol (LDL-C) from baseline to 17 months and time-adjusted percentage change in LDL-C from baseline from 3 to 18 months.
[[thumbnail_alt_text]]
Recently, many providers have become worried about the potential of certain medications to worsen transmission and outcomes in the setting of the global COVID-19 pandemic.
[[thumbnail_alt_text]]
Staying on top of oral hygiene may be connected to a lower risk of atrial fibrillation and heart failure.
[[thumbnail_alt_text]]
A new study has found that patients with heart failure with reduced ejection fraction receiving dapagliflozin decreased their risk of worsening HF or death from cardiovascular events. 
[[thumbnail_alt_text]]
Managing elevated cholesterol is one of the the key elements to decreasing negative outcomes in atherosclerotic cardiovascular disease.
[[thumbnail_alt_text]]
A patient at age 65 with high blood pressure could extend their life by more than a year with intensive treatment focused on a target systolic blood pressure of less than 120 mm Hg.